Tag : Rheumatoid

Pharma / Biotech

Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study.

Newsemia
Related Articles Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase...
Latest News

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

Newsemia
FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and...
Latest News

Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases

Newsemia
Traylor, M; Knevel, R; Cui, J; Taylor, J; Harm-Jan, W; Conaghan, PG; Cope, AP; … Scott, IC; + view all Traylor, M; Knevel, R; Cui,...
Latest News

Rheumatoid arthritis linked to other diseases before and after diagnosis, shows study

Newsemia
A Mayo Clinic-led study involving 3,276 patients has found that people with inflammatory bowel disease, Type 1 diabetes or blood clots may be at increased...
Latest News

New therapeutic target for rheumatoid arthritis and type 2 diabetes

Newsemia
There is a growing body of knowledge that points that type 2 diabetes, a chronic disease where the blood sugar increases, is an inflammatory disease....
Latest News

CreakyJoints Study Finds 74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

Newsemia
UPPER NYACK, N.Y.–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/ArthritisPoewr?src=hash" target="_blank">#ArthritisPoewr</a>–CreakyJoints Study Finds 74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy